Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

Blood

Volumn 121, Issue 22, 2013, Pages 4541-4550

  Rajala, Hanna L M ^a   Eldfors, Samuli ^a   Kuusanmäki, Heikki ^a   Van Adrichem, Arjan J ^a   Olson, Thomas ^b   Lagström, Sonja ^a   Andersson, Emma I ^a   Jerez, Andres ^c   Clemente, Michael J ^c   Yan, Yiyi ^d   Zhang, Dan ^b   Awwad, Andy ^b   Ellonen, Pekka ^a   Kallioniemi, Olli ^a   Wennerberg, Krister ^a   Porkka, Kimmo ^a   Maciejewski, Jaroslaw P ^c   Loughran, Thomas P ^b   Heckman, Caroline ^a   Mustjoki, Satu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PENN STATE CANCER INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d YORK HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN, HUMAN; STAT5B PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AMPLICON; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CELL NUCLEUS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE TARGETING; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; WHOLE EXOME SEQUENCING; CHEMISTRY; DIMERIZATION; EXOME; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETICS; HELA CELL; METABOLISM; MUTAGENESIS; MUTATION; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SRC HOMOLOGY DOMAIN;

AGED; COHORT STUDIES; DIMERIZATION; EXOME; FEMALE; GENETIC TESTING; HELA CELLS; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; MIDDLE AGED; MUTAGENESIS; MUTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SRC HOMOLOGY DOMAINS; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

MLCS; MLOWN;

EID: 84880768462     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-474577     Document Type: Article

References (35)

1. Loughran TP Jr, Kadin ME, Starkebaum G, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102(2):169-175.
2. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82(1):1-14.
3. Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006; 11(3):263-273.
4. Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006; 20(5):245-266.
5. Leblanc F, Zhang D, Liu X, Loughran TP. Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol. 2012;8(7):787-801.
6. Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20): 1905-1913.
7. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048-3057.
8. Kallio MA, Tuimala JT, Hupponen T, et al. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genomics. 2011;12:507.
9. Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T. The SWISS-MODEL repository and associated resources. Nucleic Acids Res. 2009;37(Database issue):D387-D392.
10. Becker S, Groner B, Müller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 1998;394(6689):145-151.
11. Hasegawa H, Holm L. Advances and pitfalls of protein structural alignment. Curr Opin Struct Biol. 2009;19(3):341-348.
12. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31(4):265-273.
13. Ritchie ME, Silver J, Oshlack A, et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics. 2007; 23(20):2700-2707.
14. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
15. Ambrosio R, Fimiani G, Monfregola J, et al. The structure of human STAT5A and B genes reveals two regions of nearly identical sequence and an alternative tissue specific STAT5B promoter. Gene. 2002;285(1-2):311-318.
16. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998; 16:293-322.
17. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/ oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010; 116(5):772-782.
18. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8): 1398-1405.
19. Mui AL, Wakao H, Harada N, O’Farrell AM, Miyajima A. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol. 1995;57(5):799-803.
20. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 1994;13(18): 4361-4369.
21. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11(2): 179-186.
22. Udy GB, Towers RP, Snell RG, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94(14):7239-7244.
23. Hwa V, Camacho-Hübner C, Little BM, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68(5):218-224.
24. Yao Z, Cui Y, Watford WT, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A. 2006; 103(4):1000-1005.
25. Imada K, Bloom ET, Nakajima H, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med. 1998;188(11):2067-2074.
26. Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol. 2012;3:234.
27. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996;183(3):811-820.
28. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
29. Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008; 105(42):16308-16313.
30. Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22(5): 645-655.
31. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107(3):351-362.
32. Kang K, Robinson GW, Hennighausen L. Comprehensive meta-analysis of signal transducers and activators of transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics. 2013;14:4.
33. Ariyoshi K, Nosaka T, Yamada K, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000; 275(32):24407-24413.
34. Yamada K, Ariyoshi K, Onishi M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000; 71(1):46-54.
35. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421-3429.